<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000413</url>
  </required_header>
  <id_info>
    <org_study_id>42324015.0.0000.5530</org_study_id>
    <nct_id>NCT03000413</nct_id>
  </id_info>
  <brief_title>Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial</brief_title>
  <acronym>MACANUDO</acronym>
  <official_title>Ketamine Efficacy for Acute Severe Bronchospasm in Mechanically Ventilated-critically Ill Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Nossa Senhora da Conceicao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Nossa Senhora da Conceicao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite few scientific evidence that could support the use of ketamine in adult patients
      undergoing acute bronchospasm requiring mechanical ventilation (MV), ketamine is largely
      employed in this setting. The aim of this study is therefore assess more definitively the
      real benefit of using ketamine in patients with severe bronchospasm, requiring ICU stay and
      need for MV in order to establish or refute the use of this drug as &quot;standard therapy&quot; in
      these cases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bronchospasm improvement</measure>
    <time_frame>3 hours post beginning of drug infusion</time_frame>
    <description>Maximal airway resistance reduction in hour 3-post beginning of drug infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bronchospasm improvement</measure>
    <time_frame>24 hours post beginning of drug infusion</time_frame>
    <description>Maximal airway resistance reduction in 24th hour post beginning of drug infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to weaning</measure>
    <time_frame>Time (in days) to first spontaneous breathing trial post randomization up to 28 days</time_frame>
    <description>Time (in days) to first spontaneous breathing trial post randomization up to 28 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dynamic complacence improvement</measure>
    <time_frame>3 hours and 24 hours post beginning of drug infusion</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Air trapping improvement</measure>
    <time_frame>3 hours and 24 hours post beginning of drug infusion</time_frame>
    <description>intrinsic PEEP reduction in 3 and 24h post beginning of drug infusion</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>3 hours and 24 hours post beginning of drug infusion</time_frame>
    <description>Heart rate in 3 hours and 24h post beginning of drug infusion</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 hours and 24 hours post beginning of drug infusion</time_frame>
    <description>Blood pressure variation in 3 hours and 24hours post beginning of drug infusion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Critical Illness</condition>
  <condition>Asthma</condition>
  <condition>Bronchospasm</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with acute exacerbation of COPD or status asthmaticus, undergoing controlled
             mechanical ventilation

          -  acute bronchospasm, defined as airway resistance value (Rsr max) greater than 12, use
             of inhaled therapy with bronchodilators and systemic corticosteroids

          -  patients requiring the use of continuous intravenous sedation for optimization of
             ventilation

        Exclusion Criteria:

          -  contraindication or history of previous adverse events with the use of the studied
             drugs

          -  other diagnostic potential Rsr increase of not causing bronchospasm (bronchial
             obstruction, acute respiratory distress syndrome adult, pulmonary fibrosis)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wagner Nedel, MD, MSc</last_name>
    <phone>+555133572237</phone>
    <email>wagnernedel@uol.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceição</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wagner Nedel, MD, MSc</last_name>
      <email>wagnernedel@uol.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Barbas CS, Isola AM, Farias AM, Cavalcanti AB, Gama AM, Duarte AC, Vianna A, Serpa Neto A, Bravim Bde A, Pinheiro Bdo V, Mazza BF, Carvalho CR, Toufen Júnior C, David CM, Taniguchi C, Mazza DD, Dragosavac D, Toledo DO, Costa EL, Caser EB, Silva E, Amorim FF, Saddy F, Galas FR, Silva GS, Matos GF, Emmerich JC, Valiatti JL, Teles JM, Victorino JA, Ferreira JC, Prodomo LP, Hajjar LA, Martins LC, Malbouisson LM, Vargas MA, Reis MA, Amato MB, Holanda MA, Park M, Jacomelli M, Tavares M, Damasceno MC, Assunção MS, Damasceno MP, Youssef NC, Teixeira PJ, Caruso P, Duarte PA, Messeder O, Eid RC, Rodrigues RG, Jesus RF, Kairalla RA, Justino S, Nemer SN, Romero SB, Amado VM. Brazilian recommendations of mechanical ventilation 2013. Part I. Rev Bras Ter Intensiva. 2014 Apr-Jun;26(2):89-121. Review. English, Portuguese.</citation>
    <PMID>25028944</PMID>
  </reference>
  <reference>
    <citation>Rowe BH, Sevcik W, Villa-Roel C. Management of severe acute asthma in the emergency department. Curr Opin Crit Care. 2011 Aug;17(4):335-41. doi: 10.1097/MCC.0b013e328348bf09. Review.</citation>
    <PMID>21716106</PMID>
  </reference>
  <reference>
    <citation>Heshmati F, Zeinali MB, Noroozinia H, Abbacivash R, Mahoori A. Use of ketamine in severe status asthmaticus in intensive care unit. Iran J Allergy Asthma Immunol. 2003 Dec;2(4):175-80.</citation>
    <PMID>17301376</PMID>
  </reference>
  <reference>
    <citation>Howton JC, Rose J, Duffy S, Zoltanski T, Levitt MA. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma. Ann Emerg Med. 1996 Feb;27(2):170-5.</citation>
    <PMID>8629747</PMID>
  </reference>
  <reference>
    <citation>Goyal S, Agrawal A. Ketamine in status asthmaticus: A review. Indian J Crit Care Med. 2013 May;17(3):154-61. doi: 10.4103/0972-5229.117048. Review.</citation>
    <PMID>24082612</PMID>
  </reference>
  <reference>
    <citation>Miller AC, Jamin CT, Elamin EM. Continuous intravenous infusion of ketamine for maintenance sedation. Minerva Anestesiol. 2011 Aug;77(8):812-20. Review.</citation>
    <PMID>21730929</PMID>
  </reference>
  <reference>
    <citation>Abu-Hijleh M, El-Sameed Y, Eldridge K, Vadia E, Chiu H, Dreyfuss Z, Al Rabadi LS. Linear probe endobronchial ultrasound bronchoscopy with guided transbronchial needle aspiration (EBUS-TBNA) in the evaluation of mediastinal and hilar pathology: introducing the procedure to a teaching institution. Lung. 2013 Feb;191(1):109-15. doi: 10.1007/s00408-012-9439-z. Epub 2012 Dec 4.</citation>
    <PMID>23208583</PMID>
  </reference>
  <reference>
    <citation>Allen JY, Macias CG. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med. 2005 Jul;46(1):43-50.</citation>
    <PMID>15988425</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2016</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Nossa Senhora da Conceicao</investigator_affiliation>
    <investigator_full_name>Wagner Luis Nedel</investigator_full_name>
    <investigator_title>MD, MSc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Bronchial Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

